ASXFY26 Appendix 4G and Corporate Governance Statement
other announcement
Acrux (ACR) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Google NewsACRUX Ltd (ASX: ACR) Share Price Rises on the ASX Health Care Sector – 20 August 2026 Update - Kalkine
ACRUX Ltd (ASX: ACR) Share Price Rises on the ASX Health Care Sector – 20 August 2026 Update Kalkine
ACRUX Ltd (ASX: ACR) Share Price Rises 11.11% in Latest Trading Session - Kalkine
ACRUX Ltd (ASX: ACR) Share Price Rises 11.11% in Latest Trading Session Kalkine
StockheadBiocurious: Inside Acrux’s testosterone-charged push to improve female libido
Acrux is trialling its testosterone "patchless patch" to treat low libido in menopausal women. ... Read More The post Biocurious: Inside Acrux’s testosterone-charged push to improve female libido appeared first on Stockhead.
KalkineAcrux (ASX:ACR): Is Hsdd Programme the Main Test?
Highlights Acrux is in focus after it presented its female-testosterone programme for HSDD in its latest update, creating a current test of evidence-led commercialisation. The Healthcare Stocks backdrop is shaped by clinical progress, regulatory pathways and channel expansion as Australia's market trades near record levels. The central operating question is the HSDD development programme, with trial milestones, approvals, sales traction and cash use forming the evidence-based scorecard. A rec...
Investor Presentation - Female Testosterone for HSDD
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Notification regarding unquoted securities - ACR
other announcement
Acrux Limited Releases 1.1 Million Ordinary Shares Following Vesting of Employee Performance Rights - Kalkine
Acrux Limited Releases 1.1 Million Ordinary Shares Following Vesting of Employee Performance Rights Kalkine
Notice of Extraordinary General Meeting/Proxy Form
other announcement
Update - Licensing Lenzetto for Australia for AUD5.4m
other announcement
Acrux (ASX:ACR) shares double as it banks A$5.4m from an amendment to its licensing deal for Lenzetto! - Stocks Down Under
Acrux (ASX:ACR) shares double as it banks A$5.4m from an amendment to its licensing deal for Lenzetto! Stocks Down Under
Acrux licenses Lenzetto for Australian market for AUD5.4m
other announcement
Tax-Free Edge Driving Attention Towards Acrux Shares
Highlights Acrux shareholders remain exempt from key CGT changes Tax-free dividends continue under PDF structure Market focus shifts towards defensive investment structures Acrux is drawing investor attention after confirmation that its shareholders remain protected from Australia’s upcoming capital gains tax reforms, reinforcing interest in specialised investment structures within the broader share market. Australia’s investment landscape is entering a new phase following t...
Capital Gains Tax exemptions remain in place for Acrux
other announcement
Acrux raises $1.6 million via Share Placement
capital_raise announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Acrux strategy focuses on Female Testosterone for low libido
other announcement
Acrux receives $0.55m advance on FY26 R&D Tax Incentive
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
other announcement
Notification regarding unquoted securities - ACR
other announcement
Notification regarding unquoted securities - ACR
other announcement
Acrux receives $0.4m advance on FY26 R&D Tax Incentive
other announcement
Updated September Quarter Activities Statement and App4C
other announcement